FOR IMMEDIATE RELEASE
Boca Raton, FL — Aventusoft, the company behind HEMOTAG®, Full-Spectrum Heart Failure Management System, proudly announces its successful completion of the AgeTech Collaborative™ from AARP accelerator program. We are one of only 13 companies chosen for this year’s program. With this milestone, HEMOTAG officially joins the AgeTech Collaborative ecosystem, a dynamic network of leading startups, investors, and industry experts committed to advancing solutions for aging populations.
AgeTech Collaborative™ carefully selected these exceptional startups for their potential to transform the aging experience. Each participant has undergone a rigorous evaluation process to ensure they offer forward-thinking, user-centric solutions that meet real needs across the longevity landscape. Over eight weeks, they immersed themselves in a dynamic, collaborative environment designed to accelerate growth, sharpen strategy, and strengthen product-market fit. From evidence-based design frameworks to real-world insights on reaching older consumers, these startups gained access to the critical resources needed to scale their impact.
“Completing the AgeTech Collaborative accelerator is a major step forward in our mission to transform heart failure management for older adults,” said Kaustubh Kale, Founder and CEO of HEMOTAG. “We’re excited to be part of a forward-thinking community that’s tackling the biggest challenges in aging, and we look forward to working alongside leaders in health tech, care delivery, and innovation to make heart failure manageable and not a life sentence.”
Millions of patients today are burdened by fragmented tools—apps, scales, cuffs, and wearables each relying on indirect proxies like weight, fluid shifts, or activity levels. Rather than receiving timely care, many face overwhelming complexity. HEMOTAG® offers a breakthrough alternative: a once-daily, 30-second, non-invasive test that requires no surgery, no implants, and no wearables just precise, real-time intracardiac data that empowers both clinicians and patients.
Selected for its groundbreaking technology, HEMOTAG delivers real-time performance markers across multiple heart chambers, enabling earlier interventions, reducing hospital readmissions, and significantly improving patient outcomes. Its Full-Spectrum Heart Failure Management System fills longstanding clinical gaps where traditional systems fall short—providing actionable insights across care settings from hospitals to the home.
HEMOTAG’s mission and impact directly align with the AgeTech Collaborative™ from AARP, which brings together emerging technologies and real-world needs to deliver scalable solutions that enhance the lives of older adults. By supporting physicians with actionable data and giving patients a simpler path to manage their condition, HEMOTAG is redefining what heart failure care can look like.
Through its participation in the accelerator, HEMOTAG has sharpened its go-to-market strategy, gained access to aging-focused design insights, and formed strategic partnerships that will help scale its impact across healthcare systems. With HEMOTAG now part of this powerful ecosystem, the company is poised to expand its clinical footprint and support a growing population managing chronic heart conditions at home.
About HEMOTAG
Founded in 2024 and headquartered in Boca Raton, FL, HEMOTAG® is advancing the global standard of care with its Full-Spectrum Heart Failure Management System. The company is focused on developing and commercializing the world’s first intracardiac chamber performance-based technologies—offering a new paradigm in early- to late-stage heart failure management, heart disease detection, and hemodynamics-based diagnostics. HEMOTAG’s platform combines cutting-edge quad-sensor device, mobile application, and cloud-based diagnostics to deliver clinical-grade insights across care settings—from hospitals and ambulatory centers to emergency departments and the home. These solutions are designed to fill critical gaps in cardiovascular care and enable earlier, more precise interventions.
Developed by Aventusoft, HEMOTAG is backed by non-dilutive funding from the National Institutes of Health (NIH), Department of Defense (DoD), National Science Foundation (NSF), and other federal agencies. Participation in the accelerator positions HEMOTAG for international growth and strengthens its mission to improve cardiac care for aging populations and communities globally.
Together, lets make heart failure manageable—not a life sentence. Learn more at: hemotag.com
About AgeTech Collaborative™ from AARP
The AgeTech Collaborative™ from AARP® brings together a one-of-a-kind ecosystem of key stakeholders, united in their mission to improve people’s lives as they age. Through our startup accelerator program, expert guidance, pilot testing, and connection opportunities, every part of the collaborative is designed to help participants achieve their goals.VisitAgeTech Collaborative for more details.
Media Contact
David Flores
Director of Marketing
david@hemotag.com
+1 561-234-4040